Background: Opioid-primed relapse is a global burden. Although current strategies
| INTRODUCTION
Ordinarily, typical opioid addiction and new psychoactive substance abuse lead to a chronic and relapsing disease that is characterized by a strong desire for opioid usage, increased tolerance, and withdrawal syndrome. The latest global report 1, 2 showed that opioid and new psychoactive substance dependence was one of the most common types of illicit drug dependence, affecting more than 30 million adults aged 15 to 64 years globally. Opioid dependence is directly associated with an increase in major public health issues, including infectious diseases, lack of social duty, economic functioning, and drug-related crimes. [2] [3] [4] Continual relapse due to physical and psychological dependence 5, 6 is the primary cause of detoxification failure. Thus, exploring optimal therapies for opioid relapse is a worldwide challenge. 7, 8 Although current strategies to prevent opioid relapse have improved through multidisciplinary endeavors, the relapse rate after opioid detoxification is still high and ranges from 72% to 88% after 12 to 36 months, as indicated by an epidemiological investigation. 9 Prolonged neuroendocrine system dysfunctions in opioid addicts play a role in protracted withdrawal symptoms and contribute to relapse vulnerability. Evidence from both clinical trials and animal studies has revealed that endorphins (EPs), including β-EP and its endogenous receptor, undergo a fundamental change in vivo during the opioid addiction process. 10, 11 A previous observational study investigated the decrease in β-EP in opioid addiction models, especially in the blood, spinal cord, and brain nuclei. 12, 13 Our previous work and that of others confirmed that upregulation of exogenous β-EP could attenuate withdrawal syndrome in opioiddependent rats. [14] [15] [16] [17] Moreover, studies have shown that glycylglutamine, DTgammaE, and DEgammaE, which are the active peptide and fragments derived from β-EP, respectively, present favorable effects on attenuation of opioid withdrawal symptoms. 11, 18 This evidence strongly indicates that β-EP plays an important role in preventing opioid addiction. However, inducing a sustained and increased β-EP level in vivo takes effort since the routes capable of increasing β-EP require an exogenous injection. Inspiringly, our previous study successfully constructed an adenovirus vector (Ad-NEP) that expressed exogenous β-EP, and the preliminary observational study showed a sustainable increase in β-EP in the cerebrospinal fluid (CSF), 17 which might provide an innovative treatment method for physical dependence. 19 Drug primed-induced reinstatement in conditioned place preference (CPP) is the rapid reacquisition of an extinct behavior caused by the presentation of an unconditioned stimulus in response to certain drugs. The CPP is widely used to test the ability of certain drugs to inhibit different types of reinstatement behavior and to study relapse of drug-seeking behavior and its intensity for estimation of psychological dependence. 20, 21 To determine the feasibility of gene therapy with Ad-NEP for the prevention of psychological dependence after physical dependence, the current study observed temporary β-EP expression in the lateral ventricle wall, subventricular zone and adjacent choroid plexus and the CSF 
| Propagation and purification of adenoviral vectors
As described previously, 17 the adenoviral vectors were propagated in HEK293 cells and purified by double cesium chloride gradient
centrifugation. An empty E1/E3 deletion type 5 adenovirus (Ad-Null) stored in our lab was used as the control. The final titers of Ad-NEP and Ad-Null were determined as plaque-forming units (PFUs) and adjusted to 5 × 10 10 PFUs. 
| CPP model
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CPP procedure schedule and phases: The whole CPP procedure schedule lasted 30 days, including four CPP tests for gained CPP scores in four successive phases (preconditioning, acquisition, extinction, and reinstatement). Then, four CPP scores were gained during the four successive phases.
Preconditioning phase: This procedure was similar to a previously described procedure. 22, 23 Before morphine administration for conditional training, the rats were placed into compartments and allowed to move freely for at least 30 minutes for habituation before the experiment. Then, their baseline preferences for the white or black compartment were determined over a 15-minute period. Rats that presented initial bias behavior by spending ≥70% of the total test time in each compartment were removed from the subsequent experiment.
Conditioning phase: The conditioning phase closely followed the preconditioning phase and lasted 8 days. In this phase, the rats were The CPP rat model was established following the protocol described in Experiment 2. The rats were pretreated with β-FNA and nor-BNI by icv injection 24 hours before the reinstatement behavioral test in the related groups.
| Groups and intervention
| The icv injections
All groups underwent stereotaxic surgery after the extinction phase.
After anesthetization with pentobarbital (50 mg/kg, ip, Sigma, St. Louis, MO), the rats were fixed in a stereotaxic frame (Model 51600; Stoelting Co., Wood Dale, IL). As shown in Figure 2 , a stainless steel injection cannula (28G) was inserted into the right lateral ventricle (coordinates, 1.5 mm lateral to the midline, − 0.8 mm posterior to the bregma, and −4.6 mm ventral to the skull surface). 24 Then, a single icv dose of adenovirus or normal saline was administered (volume, 10 μL; rate, 0.5 μL/minute) using a microinfusion pump (Bioanalytical Systems, Inc., Before the IHC results were quantitatively analyzed, the slides were scanned using the ScanScope system (Aperio, Vista, CA).
Thereafter, the numbers of β-EP-ir neurons in the IHC photographs were counted from 3 to 4 sections. Only neurons with crossing nuclei were selected for counting using the free NIH software "ImageJ" (2x V2.1.).
| β-EP concentration in the CSF
Ultrasound-guided CSF collection was performed on day 7 after icv injection as described previously. 29 The samples were assayed using an RIA kit (RK-022-33; Phoenix Pharmaceuticals, Inc, Phoenix, AZ)
according to the manufacturer's instructions. Briefly, the antiserum (rabbit anti-β-EP) was added to the assay tubes and incubated with CSF or standard samples for 24 hours at 4°C. The 125 I-peptide (10 000 cpm/100 μL) and radioimmunoassay (RIA) buffer were mixed well to make the tracer solution, which was added to each tube (100 μL). All tubes were incubated for 24 hours at 4°C. Goat antirabbit IgG and normal goat sera were added successively. All tubes were incubated at room temperature for 90 minutes. Finally, RIA buffer (500 μL) was added, and each tube was centrifuged (3000 rpm × 20 minutes at 4°C). The supernatants were aspirated.
A γ-counter (SN-695, Shanghai Hesuo Rihuan Photoelectric Instrument Co, Ltd, Shanghai, China) was applied to count the cpm of the pellets containing the radioligand fraction.
| Statistical analysis
The data are presented as the mean ± standard error of the mean (SEM). The data were processed using the commercially available software GraphPad Prism version 8.0 for Windows (Graph Pad Software, San Diego, CA; www.graphpad.com). An independent sample/paired t test or repeated measures/block randomized oneway analysis of variance (ANOVA) followed by post hoc analysis (Dunnett's or Newman-Keuls' test) was used to compare the CPP scores obtained from two or more control and experimental groups.
P values less than 0.05 (P < 0.05) were considered statistically significant differences.
3 | RESULTS
| The icv injection of AD-NEP induced sustained β-EP expression and increased β-EP in the rat CSF
To examine spatial and temporal β-EP expression in target neurons and the β-EP concentration in the CSF, a 21-day observational study was conducted after Ad-NEP icv injection. The lateral ventricle wall, subventricular zone and adjacent choroid plexus were the observed target domains ( Figure 1A) . 17 In the Ad-NEP group, β-EP-ir neurons (brown) were obviously observed in the target domains (indicated by red arrows), especially on day 7 after icv injection, whereas very little β-EP was detected in the other groups ( Figure 1C ). These results illustrated that Ad-NEP was transfected into epithelial cells and expressed β-EP successfully in the Ad-NEP group but not in the other three groups. Concurrently, when β-EP expression in the target neurons reached its peak, the CSF β-EP concentration in the Ad-NEP group was significantly higher than that in the other three groups on day 7 after the icv, Ad-NEP injection (P < 0.01, one-way ANOVA)
( Figure 1D and 1E).
| Therapeutic effect of increasing CSF β-EP in morphine priming-induced CPP rats
To demonstrate the therapeutic effect of increasing β-EP in the Morphine prime-induced reinstatement behavior was confirmed by the CPP test on day 7 after the icv Ad-NEP injection.
During postoperative care, one rat in the Ad-Null group died from an intracranial infection. The protocol used for the morphineprimed relapse in the rats is presented in Figure 3A . The CPP procedure is presented in Figure 3B and 3C. No significant differences were observed in the CPP scores in all groups during the preconditioning phase ( Figure 3D1 ; P > 0.05), indicating that rats with natural CPP were used in this study. During the conditioning phase, the CPP scores were significantly higher in the NS, Ad-Null, and Ad-NEP groups than in the Sham group ( Figure 3D2 ; P < 0.05), indicating that the morphine addiction rat model was successfully constructed. However, during the extinction phase, the CPP scores in all groups returned to baseline ( Figure 3D3 ; P > 0.05). Furthermore, an inefficient dose of morphine could induce seeking behavior indicated by significantly increased CPP scores in both the NS and Ad-Null groups compared to those of the Ad-NEP group ( Figure 3D4 ; P < 0.05). Furthermore, no significant differences were observed in the total distance and shuttle times among the groups, indicating similar locomotion ability (Figure 3E1 and 3E2; P > 0.05).
| Increasing β-EP in the CSF alleviates morphine-primed relapse behavior through the μ opioid receptor
To identify the specific receptor-dependent mechanism, we applied β-FNA, which is a κ opioid receptor agonist and an irreversible μ opioid receptor antagonist, and nor-BNI, which is a selective κ opioid receptor antagonist. The morphine-primed relapse protocol in the rats is presented in Figure 4A . The CPP procedure and the β-FNA and nor-BNI pretreatment protocols are presented in Figure 4B Thereafter, the transfected cells would sustainably secrete β-EP into the CSF and activate μ opioid receptors.
To identify the specific receptor-dependent mechanism, the rats were pretreated with the κ opioid receptor agonist and irreversible μ opioid receptor antagonist β-FNA and the selective κ opioid receptor antagonist nor-BNI. A previous study focused on the pharmacological characteristics of β-FNA showed that the κ opioid agonist property was maintained for approximate 4 to 6 hours after icv β-FNA injection, whereas the irreversible μ opioid receptor antagonism property lasted for more than 24 to 72 hours. 39 Therefore, the morphine-primed relapse behavior was examined 24 hours after the β-FNA icv injection to exclude the possible influence of the κ opioid agonist. Additionally, the selective κ opioid receptor antagonist nor-BNI was applied to evaluate the possible role of the κ opioid receptor in morphine-primed relapse behavior. Since our previous study showed that nor-BNI was a slow-onset, long-lasting, selective κ antagonist in vivo, we pretreated the rats with nor-BNI 24 hours before the behavioral test to reach the plateau of κ antagonism. 27, 28 Significantly increased CPP scores were observed in the β-FNA pretreated rats. Conversely, a limited reversed effect was observed in the nor-BNI pretreated rats. Robust evidence from our data and other studies 16 showed that μ, but not κ, opioid receptors played a key role in the alleviation of the effect of β-EP on morphine-primed reinstatement. Additionally, we analyzed the potential influence on impaired locomotion ability indicated by the number of shuttle times and total distance in the CPP test. Our results showed a slight but nonsignificant decrease in locomotion in the Ad-NEP group, which might contribute to the sedative characteristic of μ opioid receptor activation.
The biological characteristic of β-EP in specific brain regions, such as the lateral cerebral ventricle and nucleus arcuatus hypothalamus, has been confirmed to be involved in the addiction process. 17 Wu et al 40 found that reversal of acute morphine withdrawal syndrome behaviors contributed to a sustainable increase in endomorphin-2 in the CSF by intrathecal injection of an adenovirus engineered to express the endomorphin-2 gene. These results supported the hypothesis that opioid addiction and relapse could be improved by external secretion of the endogenous opioid peptide in targeted brain regions via CSF circulation. However, great efforts should still be undertaken to identify the specific brain regions and/or nuclei involved in this process.
The CPP induced by morphine as a conditioned stimulus is a stable and reliable behavior model for studies of drug-seeking behavior and psychological dependence in rats. 41 In the CPP model procedure, euphoria and rewarding effects that occur via a conditioned stimulus stir up psychological dependence. Due solely to this psychological dependence, reinstatement of CPP, which represents drug-seeking behavior, arises in response to a priminginduced, conditioned stimulus, context, relative cues or a stressor following natural extinction. 42 In the current study, the time during which the rats lingered in the drug-paired compartment was considered the CPP score and was used as an indicator to evaluate the intensity of drug-seeking behavior and relapse. 43 The decrease in the CPP score induced by Ad-NEP represented the alleviation of reinstatement, which indicated that this peptide might have a therapeutic effect on psychological dependence.
The recombinant adenovirus Ad-NEP applied in our study was a defective-duplicated virus that possessed significant immunogenicity and a strong infection capability in mammalian cells. The immunogenicity of adenovirus can activate the innate immune system and ultimately clear the adenovirus. The infection characteristic for the nervous system makes adenovirus a useful gene therapy tool for neurological disorders. 44 Many studies have revealed that adenovirus can be maintained in the nervous system for a certain period before activation of T lymphocytes. 45 During this period, β-EP in the CSF should reach its peak concentration and then decline gradually along with the elimination of the adenovirus according to our previous publication. 17 Based on the strategy of substitutional and decremental methadone treatment, 46 this gradual decline in the β-EP concentration could be considered an advantage of gene therapy for HE ET AL.
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relapse using an adenovirus. In this case, this delivery method for β-EP could be a potential solution to manage opioid relapse. Other vehicles, such as a lentiviral system, need to be considered as a delivery tool for the nervous system due to their natural neurotropism. For future clinical practice, an inducible gene regulation system, such as a tetracycline regulating system, is required for precise regulation of the levels and timing of target gene expression, including β-EP. A nanoparticle-modified adenovirus system with better permeation will become our research focus in the future.
In summary, this study confirmed that β-EP expressed by the recombinant adenovirus Ad-NEP could alleviate reinstatement CPP after icv administration in rats in a μ opioid receptor-dependent
manner. An adenovirus carrying the β-EP transgene may be used as a favorable solution to prevent opioid relapse.
